CD178 (Fas Ligand) Monoclonal Antibody (MFL3), APC-eFluor™ 780, eBioscience™, Invitrogen™

Description

The MFL3 monoclonal antibody reacts with mouse Fas (CD95) Ligand, a 40 kDa type II transmembrane glycoprotein. FasL is a member of the TNF family and is expressed by mouse activated T cells. The interaction of FasL with its receptor CD95 induces Fas-media

00-8222) (100 μL cell sample + 100 μL IC Fixation Buffer) or 1-step Fix/Lyse Solution (cat. 00-5333) for up to 3 days in the dark at 4°C with minimal impact on brightness and FRET efficiency/compensation. Some generalizations regarding fluorophore performance after fixation can be made, but clone specific performance should be determined empirically. Excitation: 633-647 nm; Emission: 780 nm; Laser: Red Laser. Fas ligand (FasL, CD 95L) is a type-II-membrane protein, whose N-terminus is in the cytoplasm and its C-terminal region extends into the extracellular space. Its receptor Fas (CD 95, Apo-1) is a cell-surface-type-I-membrane protein and a member of the tumor necrosis factor (TNF) and nerve growth factor (NGF) receptor family. As a member of the TNF-cytokine family FasL induces apoptosis when interacting with its receptor Fas. FasL may exist as either membrane bound (45 kD) or soluble forms (26 kD). The soluble protein can be released from cells upon cleavage by metalloproteinases. Binding of FasL to Fas leads to oligomerization of the receptor and triggers apoptotic cell death through the interaction of other proteins. FasL is predomitly expressed in activated T-lymphocytes and natural killer (NK) cells also it is expressed in the tissues of immune-privilege sites such as testis and eye. FasL expression is also reported in various tissues as thymus, liver, ovary, lung, heart and kidney. The Fas/FasL system has been shown to play a role in a number of human diseases, for example AIDS, hepatitis or cancer. It is assumed that induction of apoptosis through FasL is predomitly involved in anti-viral immune responses.